The Department of Defense today awarded Ellume USA $231.8 million to ramp up domestic production of its COVID-19 diagnostic test, the first test users can perform fully at home without a prescription. The agency expects the contract to increase daily domestic production of the test by 640,000 by December.

The contract also will procure 8.5 million of the tests for U.S. distribution. The Food and Drug Administration recently authorized emergency use of the test, which can detect the SARS-CoV-2 virus in a nasal swab sample and report the results via a smartphone app. 

Related News Articles

Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…